-
Akeso Biopharma’s H1 2022 Revenue Rises 26.8% on Penpulimab Sales
•
China-based Akeso Biopharma (HKG: 9926) reported RMB 163 million (USD 23.8 million) in revenue for H1 2022, up 26.8% year-on-year (YOY), with losses amounting to RMB 692 million (USD 23.7 million). The growth was primarily driven by sales of its PD-1 inhibitor penpulimab, which generated RMB 297 million (USD 43.2…
-
Alpha Biopharma Completes EVEREST Trial for Zorifertinib in EGFR+ NSCLC with CNS Metastases
•
Shanghai-based Alpha Biopharma announced the completion of the last patient visit in the Phase II/III EVEREST study for its next-generation EGFR inhibitor zorifertinib, targeting EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with central nervous system (CNS) metastases. Topline data is expected by the end of 2022. Study DetailsThe multi-regional…
-
eTheRNA Raises EUR 39M in Series B2 to Expand mRNA Services and Leadership
•
Belgium-based biotech firm eTheRNA has completed a Series B2 financing round, raising EUR 39 million (USD 38.9 million). The round was led by Moderna co-founder Kenneth Chien and Novalis Life Sciences LLC, with participation from existing investors including LSP (EQT Life Sciences), PMV, China’s Grand Pharma, Fund+, and Omega Fund.…
-
Sorrento Therapeutics’ Abivertinib Shows Positive Long-Term Data in NSCLC Trial
•
Sorrento Therapeutics Inc. (OTCMKTS: SRNE) announced positive long-term results for its third-generation EGFR inhibitor abivertinib in a pivotal trial for advanced non-small cell lung cancer (NSCLC). The study, conducted exclusively in China, enrolled 209 patients with EGFR-mutated lung cancer previously treated with first-generation EGFR inhibitors. Trial Results The data is…
-
Porton Biologics and Royaltech Med Partner on Bacterial and mRNA Drug Platforms
•
China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has partnered with Suzhou Royaltech Med Co., Ltd to establish bacterial (Listeria) and mRNA drug platform technologies. The collaboration aims to integrate both firms’ resources and capabilities, though financial terms were not disclosed. Company Profiles Strategic OutlookThe partnership will…
-
NMPA Suspends UCB’s Keppra Over Labeling Issues, Prompting Recall
•
The National Medical Products Administration (NMPA) has suspended approval for UCB’s Keppra (levetiracetam) concentrated solution after an overseas inspection uncovered inconsistent expiration date labeling. The decision affects batches manufactured and packaged abroad, with UCB initiating a voluntary recall and cooperating to resolve the issue. Company ResponseUCB announced the recall of…
-
Biocytogen and Merck KGaA Ink Global Deal for RenMice Platform Licensing
•
Sino-US contract research organization (CRO) Biocytogen Pharmaceuticals (Beijing) Co., Ltd has entered into a global licensing agreement with Germany-based Merck KGaA, granting Merck exclusive rights to its RenMice platform. The platform will be used to discover and develop human antibodies against unlimited drug targets, with Merck holding full rights to…
-
3SBio Inc. Reports H1 2020 Revenue of RMB 3.091B, Net Profit Up 6.19%
•
China-based 3SBio Inc. (HKG: 1530) reported its H1 2020 financial results, with revenue of RMB 3.091 billion (USD 451.5 million), a 0.51% decrease year-on-year (YOY). Net profits rose 6.19% YOY to RMB 955 million (USD 145.3 million). R&D investment increased 14.7% to RMB 294 million (USD 42.9 million). Core Products3SBio’s…
